News

As Seen In
9 Challenges Keeping Cell And Gene Therapy Executives Up At Night
Despite recent progress in regenerative medicine, cell and gene therapy executives are still pioneering many...
Press Release
RepliCel Life Sciences Announces Signed Licensing and Co-Development Deal for Greater China
Skin rejuvenation and tendon regeneration products to be commercialized in Greater China in partnership with...
As Seen In
Is the Age-Old Quest for a Baldness Cure Reaching Its End?
Click here to read the full article and interview as it appears in The New...
As Seen In
RepliCel's regenerative technology could take the "Polar Silk Road" to China
New opportunities are arising at every turn for the regenerative medicine community. READ ARTICLE ...
Press Release
RepliCel Life Sciences Now Finalizing its Strategic Investment Partnership with China-based YOFOTO
A revised binding term sheet reflects improved terms and positions the parties for closing the...
As Seen In
Regenerative Medicine Company's China Deal is 'Dramatically Transformational'
Echelon Wealth Partners detailed the terms and impact of this cell therapy developer's recent alliance...
Press Release
RepliCel CEO Provides 2018 Shareholder Update
With a new Asian partnership and 2017 deliverables met, RepliCel is primed and ready for...
As Seen In
From stem cells to revenue: Bringing regenerative medicine to the masses
RepliCel lands Asian partnership to optimize the development of its biotech solutions for chronic conditions....
Press Release
RepliCel Life Sciences Lands Commitment for Key Investment Partnership
YOFOTO (China) Health Industry Co. Ltd to Invest in Becoming RepliCel's Strategic Partner for Greater...
Events
2018 EBD Biotech Showcase
RepliCel presented and conducted one-on-one partnering meetings.
As Seen In
RepliCel CEO: Anticipating the Approval of Their Dermal Injector, its Impact in Europe and Beyond
Click here to read the full article and interview as it appears in Life Science:...
As Seen In
Japan is Fertile Ground for Biotech Deal
Click here to read the full article as it appears in the Streetwise Reports: The...
Press Release
RepliCel Life Sciences Successfully Closes Financing
Shareholders commit to non-brokered private placement in clear support of the Company’s partnership strategy VANCOUVER,...
As Seen In
Company Uses Patients' Own Cells to Put an End to Baldness, Aging Skin and Tendon Degeneration
Company Uses Patients' Own Cells To Put An End To Baldness, Aging Skin And Tendon...
As Seen In
Regenerative medicine: Interview with a game-changing leader
Regenerative medicine is a game-changing area of medicine. It has the potential to fully heal...
Press Release
RepliCel’s Partnership Initiatives Mature into Licensing Negotiations
Due diligence and confidential discussions now moving into negotiations for products in both the tendon...
Press Release
RepliCel Showcases First Fully-Functional Prototypes of its Next-Generation Dermal Injector
Delivery of RepliCel’s patented prototypes kick-starts functional testing, matures licensing discussions, and confirms commercialization scheduleVANCOUVER,...
As Seen In
Analyst Says Cell Therapy Company’s Move Decreases Risk
Click here to read the full article as it appears in the Streetwise Reports (08/23/17)....
As Seen In
Your Hair Follicles May Hold the Key to Younger Looking Skin
Click here to read the full article as it appears in the New York Daily...
Press Release
RepliCel Life Sciences Joins MedCision’s ThawSTAR® Early Adopter Program
Regenerative Medicine Company to Adopt ThawSTAR® Cell Thawing Systems to De-Risk Cell Therapy Clinical TrialVANCOUVER,...

DISCLAIMER:
The information in these press releases is historical in nature, has not been updated, and is current only to the date indicated in the particular press release. This information may no longer be accurate and therefore you should not rely on the information contained in these press releases. To the extent permitted by law, RepliCel Life Sciences Inc. and its employees, agents and consultants exclude all liability for any loss or damage arising from the use of, or reliance on, any such information, whether or not caused by any negligent act or omission.

THIRD PARTY CONTENT
Please note that any opinion, estimates or forecasts made by the authors of these statements are theirs alone and do not represent opinions, forecasts or predictions of RepliCel Life Sciences Inc. or its management. RepliCel Life Sciences Inc. does not, by its reference or distribution of these links imply its endorsement of, or concurrence with, such information, conclusions or recommendations.